BIAL to present at GBA1 Meeting 2025 on Parkinson’s treatment
BIAL, a biopharmaceutical company focused on neurosciences and rare diseases, will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held 5-7 June 2025, in Montreal, Canada.
The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic science to clinical trials.
BIAL will be presenting the ACTIVATE study, a Phase II trial evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease who have a mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The presentation will happen in the session ‘Small molecules targeting GBA1’ and will focus on study design, genetic testing, recruitment challenges, and trial status.
Raquel Costa, the study lead, said: “We’re witnessing a growing enthusiasm around the potential of BIA 28-6156 across the Parkinson’s community and are eager to present further insights into the ACTIVATE study design at the upcoming GBA1 Meeting. We believe this investigational therapy could represent a significant step forward with the potential to be a much-needed disease-modifying treatment option for patients living with GBA-PD.”
BIA 28-6156 is a first-in-class, small molecule for once-daily oral administration, allosteric activator of beta-glucocerebrosidase (GCase), in development for the treatment of patients with GBA-PD. By increasing the activity of GCase, BIA 28-6156 may be the first drug to directly modify the underlying cause of the disease in this group of patients by re-establishing the sphingolipid recycling1,2.
The ACTIVATE study (clinicaltrials.gov: NCT05819359) is a Phase II, multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in GBA-PD patients. The study has enrolled 273 genetically confirmed GBA-PD patients, several of whom have already completed the trial, across 85 sites in Europe and North America.
Topline data from this Phase II study is expected to be released in the second quarter of 2026.
Presentation details
Date and Time: 5 June 2025; 12:00-12:20 PM
Session: Small molecules targeting GBA1 – Session 2
Presenter: Raquel Costa, Senior Manager, Clinical Operations, BIAL
Location: Delta Hotels, Montreal, Canada
Megan Thomas, Multimedia Editor, DDW
